Stockscreener 앱 받기
1.91
4.97%
0.10
전일 마감가:
$1.81
열려 있는:
$1.87
하루 거래량:
396.09K
Relative Volume:
0.75
시가총액:
$83.54M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.83%
1개월 성능:
-14.03%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.84
$1.91
1주일 범위
$1.80
$2.19
52주 변동 폭
$1.42
$2.30
Mindwalk Holdings Corp Stock (HYFT) Company Profile
HYFT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HYFT
Mindwalk Holdings Corp
|
1.90 | 83.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.45 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mindwalk Holdings Corp Stock (HYFT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-10-25 | 개시 | The Benchmark Company | Buy |
Mindwalk Holdings Corp 주식(HYFT)의 최신 뉴스
MindWalk (HYFT) Announces Share Repurchase Plan - GuruFocus
MindWalk Holdings (HYFT) Announces 2.3M Share Buyback Program - GuruFocus
MindWalk Holdings Corp. authorizes a Buyback Plan. - MarketScreener
MindWalk Holdings Corp. announces an Equity Buyback for 2,300,000 shares. - MarketScreener
MindWalk Holdings announces 2.3M share buyback program - MSN
MindWalk announces $2.3 million share repurchase program By Investing.com - Investing.com Nigeria
MindWalk Holdings Initiates Share Repurchase Program to Enhance Shareholder Value - TipRanks
MindWalk announces $2.3 million share repurchase program - Investing.com India
MindWalk Announces Share Repurchase Program - The Joplin Globe
MindWalk Unveils Dual-Pathway Regimen in Longevity Therapeutics - MSN
MindWalk Holdings Corp. (HYFT) Surges with 45% Revenue Growth and Strategic AI-Focused Rebrand - Insider Monkey
MindWalk expands GLP-1 program with AI-discovered longevity pathway By Investing.com - Investing.com Nigeria
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity - The AI Journal
Accelerating Drug Discovery through First End-to-End Bio-Native AI Platform (09/22/2025 00:00 - MarketScreener
MindWalk stock soars on dual-pathway GLP-1 therapeutic advancement By Investing.com - Investing.com South Africa
MindWalk stock soars on dual-pathway GLP-1 therapeutic advancement - Investing.com
MindWalk (HYFT) Unveils Breakthrough in GLP-1 Therapeutic Progra - GuruFocus
MindWalk expands GLP-1 program with AI-discovered longevity pathway - Investing.com
MindWalk advances AI-designed GLP-1 program with first-in-class dual-pathway regimen for aging and longevity - MarketScreener
MindWalk : Accelerating Drug Discovery through First End-to-End Bio-Native AI Platform - MarketScreener
How MindWalk Holdings' Rebranding and Improved Earnings May Impact HYFT Investors - Yahoo Finance
MindWalk Holdings Reports Strong Revenue Growth and Improved Margins - TipRanks
MindWalk Holdings Corp (HYFT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
MindWalk Holdings Corp (HYFT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Rebranding - GuruFocus
MindWalk Holdings Reports Q3 2025 Financial Results and Strategic Growth - TipRanks
MindWalk Holdings Corp reports results for the quarter ended July 31Earnings Summary - TradingView
MindWalk Holdings Corp. Reports Earnings Results for the First Quarter Ended July 31, 2025 - MarketScreener
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly - PharmiWeb.com
Earnings call transcript: MindWalk Inc. reports strong Q1 2025 performance, rebrands from ImmunoPrecise Antibodies - Investing.com UK
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet - Business Wire
MindWalk Holdings Reports Record Revenue and Strategic Divestiture - TipRanks
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet | FinancialContent - FinancialContent
MindWalk : 2025 Combined Financial Statements - MarketScreener
MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025 - Business Wire
MindWalk Holdings Corp.HYFTStock Price Today - Zacks Investment Research
HYFT Stock Price and Chart — NASDAQ:HYFT - TradingView
ImmunoPrecise Antibodies rebrands as MindWalk, changes ticker to HYFT By Investing.com - Investing.com Canada
HYFT's Rebranding: A Strategic Pivot in Biotech's AI-Driven Future - AInvest
ImmunoPrecise Antibodies rebrands as MindWalk, changes ticker to HYFT - Investing.com
Immunoprecise rebrands as Mindwalk, announces Nasdaq ticker change to "HYFT" - MarketScreener
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” - FinancialContent
Leading Biotech ImmunoPrecise Antibodies Joins Major H.C. Wainwright Investment Conference in New York - Stock Titan
AI-Powered Universal Dengue Vaccine Breakthrough: ImmunoPrecise's LENSai Platform Advances to Animal Studies - Stock Titan
Strategic Acquisition: AVS Bio Expands Global Biologics Reach with ImmunoPrecise Europe Buyout - Stock Titan
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA - Business Wire
Mindwalk Holdings Corp (HYFT) 재무 분석
Mindwalk Holdings Corp (HYFT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.12%
자본화:
|
볼륨(24시간):